M. del Valle Rubido

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

S. Fauser, J. Sahni, E. Nogoceke, 2020, JAMA ophthalmology.

A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

J. Sevigny, P. Fontoura, D. Umbricht, 2019, Science Translational Medicine.

Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II

Christopher H. Chatham, T. Charman, E. Loth, 2018, Autism research : official journal of the International Society for Autism Research.

Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger’s Versus Healthy Controls: A Cross-Sectional Analysis

E. Hollander, F. Shic, J. McCracken, 2020, Journal of Autism and Developmental Disorders.

The Impact of Inherited Retinal Diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a Cost-of-Illness Perspective

M. Michaelides, Avril Daly, Orla Galvin, 2020, Clinical ophthalmology.

In Search of Biomarkers for Autism Spectrum Disorder

E. Hollander, F. Shic, J. McCracken, 2018, Autism research : official journal of the International Society for Autism Research.

A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

E. Hollander, F. Shic, J. McCracken, 2016, Neuropsychopharmacology.